Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...

In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research ...

Johnson & Johnson is set to report earnings before the bell Wednesday, with analysts expecting revenue and profit growth from ...

Key Takeaways Johnson & Johnson's fourth quarter sales met estimates, while net income fell short.After adjusting for ...

Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter sales ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Ph.D., Global Therapeutic Head, Oncology, Johnson & Johnson Innovative Medicine. “By combining our expertise in innovative medicine and medical devices, Johnson & Johnson is uniquely positioned to ...

The university named Dr. Kirk Calhoun as the interim president.

The director of the National Institutes of Health, Dr. Monica Bertagnolli, announced that she will step down Friday, 14 ...

After decades of a diversified healthcare business model, Johnson & Johnson has announced it plans to split off its consumer health division from its pharma and medical device operations.